Publications

Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, Ataullakhanov R, Miheecheva N, Frenkel F, Wang Y, Zhang M, Hawke D, Han L, Zhou S, Zhang Y, Wang Z, Decker WK, Sonnemann HM, Roszik J, Forget MA, Davies MA, Bernatchez C, Yee C, Bassett R, Hwu P, Du X, Lizee G. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 9(7), 7/2021. PMCID: PMC8268925.

Pan K, Chiu Y, Chen M, Wang J, Lai I, Singh S, Shaw R, Yee C. In Silico Defined SARS-CoV2 Epitopes May Not Predict Immunogenicity to COVID19. bioRxiv, 7/2021. e-Pub 7/2021. PMCID: PMC8282092.

Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, Singh S, Shaw R, MacCoss M, Yee C. Immunogenic SARS-CoV2 Epitopes Defined by Mass Spectrometry. bioRxiv, 7/2021. e-Pub 7/2021. PMCID: PMC8312890

Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 6/2021. e-Pub 6/2021. PMCID: PMC8199881.

Kohli K, Yao L, Nowicki TS, Zhang S, Black RG, Schroeder BA, Farrar EA, Cao J, Sloan H, Stief D, Cranmer LD, Wagner MJ, Hawkins DS, Pillarisetty VG, Ribas A, Campbell J, Pierce RH, Kim EY, Jones RL, Riddell SR, Yee C, Pollack SM. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. J Immunother Cancer 9(5), 5/2021. PMCID: PMC8108691.

Hasan, F, Chiu Y, Shaw RM, Wang J, Yee C. Hypoxia acts as an environmental cue for the human tissue resident memory T cell differentiation program. Journal of Clinical Investigation. JCI Insight 6(10), 5/2021. e-Pub 5/2021. PMCID: PMC8262358.

Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 10(1):1927313, 5/2021. e-Pub 5/2021. PMCID: PMC8158025.

Lim SA, Moon Y, Shin MH, Kim TJ, Chae S, Yee C, Hwang D, Park H, Lee KM. Hypoxia-Driven HIF-1α Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways. Cancers (Basel) 13(8), 4/2021. e-Pub 4/2021. PMCID: PMC8071270.

Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer 9(2), 2/2021. PMCID: PMC7887353.

Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, *Yee C, *Abudayyeh A (co-corresponding authors) . Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1):1877415, 2/2021. e-Pub 2/2021. PMCID: PMC7872057.

Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, *Yee C, *Lizée G (*co-corresponding authors). Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 10/2020. e-Pub 10/2020. PMCID: PMC7577998.

Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A.  Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 8(2), 10/2020. PMCID: PMC7537330.

An X, Martinez-Paniagua M, Rezvan A, Fathi M, Singh S, Biswas S, Pourpak M, Yee C, Liu X, Varadarajan N. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. bioRxiv, 7/2020. e-Pub 7/2020. PMCID: PMC7386485.

Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee C. Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology 159(1):306-319.e12, 7/2020. e-Pub 3/2020. PMCID: PMC7387152

Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee C. Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells. Cancer Immunol Res 8(6):794-805, 6/2020. e-Pub 3/2020. PMCID: PMC7269845.

Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 4/2020. e-Pub 4/2020. PMID: 32296058.

Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SM. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer 8(1), 4/2020. PMID: 32269142

Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319, 11/2019. e-Pub 11/2019. PMCID: PMC6868691.

Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640-2653, 11/2019. e-Pub 4/2019. PMCID: PMC6814517.

Zhang, Shihong ; Kohli, Karan ; Black, R Graeme ; Yao, Lu ; Spadinger, Sydney M ; He, Qianchuan ; Pillarisetty, Venu G ; Cranmer, Lee D ; Van Tine, Brian A ; Yee, Cassian ; Pierce, Robert H ; Riddell, Stanley R ; Jones, Robin L ; Pollack, Seth M; Zhang, Shihong (correspondence author) ; Zhang, Shihong (record owner. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer immunology research 7(8):1237-1243, 8/2019.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res 7(8):1237-1243, 8/2019. e-Pub 6/2019. PMCID: PMC6677581.

Kim TJ, Park G, Kim J, Lim SA, Kim J, Im K, Shin MH, Fu YX, Del Rio ML, Rodriguez-Barbosa JI, Yee C, Suh KS, Kim SJ, Ha SJ, Lee KM. CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun 10(1):3258, 7/2019. e-Pub 7/2019. PMCID: PMC6646315.

Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 5/2019. e-Pub 5/2019. PMCID: PMC6562561.

Fan J, Liang H, Ji X, Wang S, Xue J, Li D, Peng H, Qin C, *Yee C,* Shao Y (*co-corresponding authors). CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. Nat Commun 10(1):2257, 5/2019. e-Pub 5/2019. PMCID: PMC6529452.

Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization with Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol 10:496, 2019. e-Pub 4/2019. PMCID: PMC6465515.

Ott PA, Dotti G, Yee C, Goff SL. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book 39:e70-e78, 1/2019. e-Pub 5/2019. PMID: 31099621.

Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 1/2019. e-Pub 1/2019. PMCID: PMC6322290.

Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 10/2018. e-Pub 10/2018. PMID: 30305177.

Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, Chen A, Bao Y, Zhou C, Li S, Yee C, Li Y. ImmTAC/Anti-PD-1 Combination to Enhance Killing of Cancer cells by Reversing Treg-mediated Immunosuppression. Immunology. e-Pub 5/2018. PMID: 29791021.

Fan J, Liang H, Shen T, Wang S, Ji X, Yee C, Lu F, Shao Y. Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cell Immunol. e-Pub 5/2018. PMID: 29773224.

Yee C. Adoptive T cell therapy: points to consider. Curr Opin Immunol 51:197-203, 4/2018. e-Pub 5/2018. PMID: 29730057.

Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. Oncotarget 9(19):14764-14790, 3/2018. e-Pub 2/2018. PMCID: PMC5871077.

Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res 5(8):618-629, 8/2017. e-Pub 6/2017. PMID: 28630054.

Yee C, Lizee GA. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J 23(2):144-148, Mar/Apr, 3/2017. PMID: 28410303.

Yee C. From the Guest Editor. Cancer J 23(2):95-96, Mar/Apr 3/2017. PMID: 28410295.

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo. Sci Immunol 2(8), 2/2017. e-Pub 2/2017. PMCID: PMC5371351.

Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol. e-Pub 6/2016. PMID: 27269940.

Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 213(7):1133-9, 6/2016. e-Pub 5/2016. PMCID: PMC4925025.

Yee C, Lizee G, Schueneman AJ. Endogenous T-Cell Therapy: Clinical Experience. Cancer J 21(6):492-500, Nov-Dec, 11/2015. PMCID: PMC26588682.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2(1):36, 2014. e-Pub 10/2014. PMCID: PMC4196009.

Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, *Yee C, *Lee KM, *Kim TW (*co-corresponding authors). API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res 74(13):3556-66, 7/2014. e-Pub 4/2014. PMID: 24769442.

Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev 257(1):250-63, 1/2014. PMID: 24329802.

Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, *Yee C, *Nghiem P (*co-corresponding authors). Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2(1):27-36, 1/2014. PMCID: PMC3888869.

Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res 19(17):4550-2, 9/2013. e-Pub 8/2013. PMCID: PMC3830944.

Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD (co-corresponding authors: CY and PDG). Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5(174):174ra27, 2/2013. PMCID: PMC3678970.

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7(2):e32165, 2012. e-Pub 2/2012. PMCID: PMC3288075.

Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118(18):4564-70, 9/2012. e-Pub 2/2012. PMCID: PMC3361576.

Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 109(12):4592-7, 3/2012. e-Pub 3/2012. PMCID: PMC3311364.

Lee SM, Yee C. Another LAP in the race. Cancer Discov 2(2):107-9, 2/2012. PMID: 22585852.

Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17(7):1664-73, 4/2011. e-Pub 2/2011. PMID: 21325070.

Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol 184(11):6514-21, 6/2010. e-Pub 5/2010. PMCID: PMC3313650.

Yee C,. Adoptive therapy using antigen-specific T-cell clones. Cancer J 14(4):367-73, 1/2010.

Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4(3):e4749, 2009. e-Pub 3/2009. PMCID: PMC2650617.

Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358(25):2698-703, 6/2008. PMCID: PMC3277288.

Gunn J, Wallen H, Veiseh O, Sun C, Fang C, Cao J, *Yee C, *Zhang M. A multimodal targeting nanoparticle for selectively labeling T cells. Small 4(6):712-5, 6/2008. PMCID: PMC2692349.*co-corresponding authors

Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1):229-35, 1/2008. e-Pub 10/2007. PMCID: PMC2200808.

Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175(4):2261-9, 8/2005. PMID: 16081794.

Yee C. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med 3(1):17, 4/2005. e-Pub 4/2005. PMCID: PMC1131930.

Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9(5):757-64, 5/2004. PMID: 15120337.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99(25):16168-73, 12/2002. e-Pub 11/2002. PMCID: PMC138583.

Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734-8, 10/2002. PMID: 12384702.

Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2(6):409-19, 6/2002. PMID: 12189383.

Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 192(11):1637-44, 12/2000. PMCID: PMC2193107.

*Lee PP, *Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-85, 6/1999. PMID: 10371507 *co-first authors.

Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162(4):2227-34, 2/1999. PMID: 9973498.

Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283(5403):848-51, 2/1999. PMID: 9933169.

Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 157(9):4079-86, 11/1996. PMID: 8892642.

Yee C, Messner HA, Minden MD. Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol 148(3):426-9, 9/1991. PMID: 1918171.

Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74(2):798-804, 8/1989. PMID: 2787680.